CW January 2005
Volume 14Issue Number 1 January 2005 ISSN 10593802 Subcu Campath in CLL: Effective and ConvenientA trial of Campath (alemtuzumab, Berlex) in patients with chronic lymphocytic leukemia (CLL) showed that giving the agent via the more convenient subcutaneous (s.c.) route has similar efficacy to intravenous (i.v.) administration, according to a 46th Annual Meeting of the American Society of Hematology presentation.
Go to Previous Page Go to Next Page Source & Additional Reading Investigator Stephan Stilgenbauer, Department of Internal Medicine, University of Ulm, Germany. 46th Annual Meeting of the American Society of Hematology presentation. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
